Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 5, 2014, Pages 1325-1329

  Malcolm, R Karl ^a   Lowry, Deborah ^b   Boyd, Peter ^a   Geer, Leslie ^c   Veazey, Ronald S ^d   Goldman, Laurie ^c   Klasse, P J ^e   Shattock, Robin J ^f   Moore, John P ^f  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c Particle Sciences   (United States)

^d TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CMPD167; HIV microbicides; Pre exposure prophylaxis; PrEP; Rectal gels; Vaginal HEC gels; Vaginal rings

Indexed keywords

HYDROXYETHYLCELLULOSE; MEDROXYPROGESTERONE ACETATE; N [3 [4 (3 BENZYL 1 ETHYL 5 PYRAZOLYL) 1 PIPERIDINYLMETHYL] 4 (3 FLUOROPHENYL)CYCLOPENTYL] N METHYLVALINE; SILASTIC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; N-(3-(3-FLUOROPHENYL)-4-((4-(3-BENZYL-1-ETHYLPYRAZOL-5-YL)PIPERIDIN-1-YL)METHYL)CYCLOPENTYL)-N-METHYLVALINE; PYRAZOLE DERIVATIVE; VALINE; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG TISSUE LEVEL; DRUG VAGINAL LEVEL; GASTROINTESTINAL TRANSIT; GEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RECTAL FLUID; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHESUS MONKEY; TIME TO MAXIMUM PLASMA CONCENTRATION; VAGINA DISCHARGE; VAGINA RING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY FLUID; CHEMISTRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVAGINAL DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RECTAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANIMALS; ANTI-HIV AGENTS; BODY FLUIDS; CCR5 RECEPTOR ANTAGONISTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; MACACA MULATTA; MALE; MASS SPECTROMETRY; PYRAZOLES; RECEPTORS, HIV; VALINE;

EID: 84898457539     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt506     Document Type: Article

References (19)

1. Friend DR, Kiser PF. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res 2013; 99: 391-400.
2. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012; 2: a007385.
3. Karim QA, Karim SSA, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
4. Klasse PJ, Shattock R, Moore KP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Ann Rev Med 2008; 59: 455-71.
5. Balzarini J, Schols D. Combination of antiretroviral drugs as microbicides. Curr HIV Res 2012; 10: 53-60.
6. Forbes CJ, Lowry D, Geer L et al. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 2011; 156: 161-9.
7. Curran RM, Donnelly L, Morrow RJ et al. Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine 2009; 27: 6791-8.
8. Malcolm RK, Veazey RS, Geer L et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 2012; 56: 2251-8.
9. Nel A,Smythe S, Young K et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51: 416-23.
10. Malcolm RK, Edwards K-L, Kiser P et al. Advances in microbicide vaginal rings. Antiviral Res 2010; 88 Suppl 1: S30-9.
11. Grant RM, Lama JR, Anderson PL et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-99.
12. Massud I, Aung W, Martin A et al. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. J Virol 2013; 87: 8952-61.
13. Veazey RS, Klasse PJ, Schader SM et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438; 99-102.
14. Veazey RS, Springer MS, Marx PA et al. Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 2005; 11: 1293-4.
15. Malcolm RK, Forbes CJ, Geer L et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 2013; 68: 678-83.
16. Bulletti C, de Ziegler D, Flamigni C et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod 1997; 12: 1073-9.
17. Cicinelli E, de Ziegler D, Morgese S et al. 'First uterine pass effect' is observed when estradiol is placed in the upper but not lower third of the vagina. Fertil Steril 2004; 81: 1414-6.
18. Nuttall J, Kashuba A, Wang R et al. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob Agents Chemother 2012; 56: 103-9.
19. Hendrix CW, Chen BA, Guddera V et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013; 8: e55013.